{"product_id":"srpt-marketing-mix","title":"(SRPT) Sarepta Therapeutics, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Sarepta Therapeutics, Inc. 4P's Marketing Mix Analysis summarizes the company’s products (DMD-focused therapies), pricing strategy, distribution channels, and promotion tactics to show how it competes in rare-disease biotech; the page includes a real preview\/sample of the analysis so you can review format and content before buying—purchase the full version for the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEXONDYS 51 exon 51 skipping\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEXONDYS 51 is Sarepta Therapeutics, Inc.’s approved Duchenne muscular dystrophy therapy for patients with confirmed mutations amenable to exon 51 skipping. It uses an RNA-targeted phosphorodiamidate morpholino oligomer, or PMO, to help restore dystrophin production in a narrow patient group. That mutation-specific fit makes it a core product in Sarepta Therapeutics, Inc.’s DMD franchise and a key precision-medicine asset. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVYONDYS 53 exon 53 skipping\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVYONDYS 53 is Sarepta Therapeutics, Inc.'s approved Duchenne muscular dystrophy therapy for patients with mutations amenable to exon 53 skipping. It uses the same phosphorodiamidate morpholino oligomer exon-skipping platform as EXONDYS 51, which helps Sarepta reach a broader slice of the DMD mutation pool. In 2024, the company reported total net product revenue of $1.38 billion, with PMO franchise demand still supporting sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMONDYS 45 exon 45 skipping\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMONDYS 45 is Sarepta Therapeutics, Inc.'s exon 45-skipping therapy for Duchenne muscular dystrophy patients with a confirmed exon 45 amenable mutation, a slice that is roughly 8% of DMD cases. It extends Sarepta Therapeutics, Inc.'s exon-skipping platform across more genetic subgroups, reinforcing a mutation-defined rare-disease strategy. In 2024, Sarepta Therapeutics, Inc. reported $1.6 billion in net product revenue, showing how this precision franchise supports sales across multiple DMD genotypes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSRP 5051 exon 51 peptide conjugate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSRP 5051 exon 51 peptide conjugate is Sarepta Therapeutics, Inc.’s next-gen exon-skipping asset for Duchenne muscular dystrophy, built to target exon 51 of dystrophin pre-mRNA. It uses a peptide-conjugated PMO to aim for better muscle delivery than earlier PMOs, and exon 51 remains relevant for about 13% of DMD patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNext-gen RNA therapeutic\u003c\/li\u003e\n\u003cli\u003eExon 51 target\u003c\/li\u003e\n\u003cli\u003eDelivery-focused design\u003c\/li\u003e\n\u003cli\u003eNo disclosed product revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSRP 9001 and SRP 9003 gene therapy programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSRP-9001, now Elevidys, is Sarepta’s Duchenne muscular dystrophy gene therapy and the clearest proof that the Company is moving beyond exon skipping into viral gene transfer. SRP-9003 extends that reach into limb-girdle muscular dystrophies, giving Sarepta a broader rare-disease platform with higher long-term pricing power than single-asset RNA therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003cli\u003e\u003c\/ul\u003e\n\u003cp\u003eIn 2024, Sarepta posted about $1.8 billion in net product revenue, and gene therapy is the main growth lever behind that base. The pitch is simple: one-time delivery, faster clinical impact, and a larger addressable market than any single exon-skipping product.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta’s DMD Franchise: A $1.8B Revenue Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc.'s Product mix is built on Duchenne muscular dystrophy therapies: EXONDYS 51, VYONDYS 53, AMONDYS 45, and Elevidys. In 2024, net product revenue was about $1.8 billion, showing the franchise’s scale. The portfolio blends mutation-specific PMOs with gene therapy, so each asset targets a distinct patient group.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eType\u003c\/th\u003e\n\u003cth\u003eKey point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEXONDYS 51\u003c\/td\u003e\n\u003ctd\u003ePMO\u003c\/td\u003e\n\u003ctd\u003eExon 51\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVYONDYS 53\u003c\/td\u003e\n\u003ctd\u003ePMO\u003c\/td\u003e\n\u003ctd\u003eExon 53\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMONDYS 45\u003c\/td\u003e\n\u003ctd\u003ePMO\u003c\/td\u003e\n\u003ctd\u003eExon 45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElevidys\u003c\/td\u003e\n\u003ctd\u003eGene therapy\u003c\/td\u003e\n\u003ctd\u003eDMD delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, company-specific 4P analysis of Sarepta Therapeutics, Inc.'s Product, Price, Place, and Promotion strategy, grounded in real market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCondenses Sarepta Therapeutics’ 4Ps into a quick, decision-ready snapshot for fast alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists primary, reputable sources that let investors verify Sarepta Therapeutics' market, pricing, and competitive assumptions quickly and traceably.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCambridge Massachusetts headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics is headquartered in Cambridge, Massachusetts, and the site anchors its corporate, research, and commercial teams. It is the company’s main base for rare-disease development, where gene therapy and RNA-focused programs are managed. In 2025, Sarepta’s Cambridge hub sat at the center of a business that serves patients in 50+ countries through its Duchenne franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States specialty rare disease channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. uses U.S. specialty rare-disease channels, where neuromuscular specialists manage Duchenne muscular dystrophy (DMD) care instead of retail pharmacies. This fits a small, genetically defined patient pool, since DMD affects about 1 in 3,500 to 5,000 male births. In 2025, this channel stays central because access, prior auth, and infusion\/dispensing coordination matter more than mass-market reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetic testing driven patient access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAccess starts with confirmed dystrophin mutation testing, because exon eligibility decides whether a patient can receive EXONDYS 51, VYONDYS 53, or AMONDYS 45. That makes diagnostics part of distribution, not just diagnosis. In Duchenne muscular dystrophy, where about 1 in 3,500 to 5,000 male births are affected, fast genetic testing directly shapes patient identification and treatment reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRoche ex U S collaboration for SRP 9001\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. uses its F. Hoffmann-La Roche partnership to push SRP-9001 beyond the United States, giving the therapy a commercial route in ex-U.S. markets that Sarepta would not cover alone. The 2019 deal brought Sarepta $1.15 billion upfront and can add up to $1.7 billion in milestones, so the place strategy is tied to scale, cash, and reach. Roche’s global network supports access in major markets across Europe, Asia, and Latin America, which helps SRP-9001 move faster where Sarepta has no direct footprint.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands SRP-9001 beyond the U.S.\u003c\/li\u003e\n\u003cli\u003eRoche handles ex-U.S. commercialization\u003c\/li\u003e\n\u003cli\u003eSupports faster international market access\u003c\/li\u003e\n\u003cli\u003eDeal value: $1.15B upfront\u003c\/li\u003e\n\u003cli\u003eMilestones can reach $1.7B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAcademic and hospital collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. works with 5 key academic and hospital collaborators: Nationwide Children’s Hospital, Duke University, Genethon, Lysogene, and StrideBio. These links support research, development, and clinical translation, and help place programs in specialist care settings where rare-disease expertise and trial access are strongest.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5 active named collaborators\u003c\/li\u003e\n\u003cli\u003eSupports research to clinical translation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta’s Cambridge Hub Powers Specialty Gene Therapy Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. places its core operations in Cambridge, Massachusetts, where R\u0026amp;D, commercial, and gene therapy work are run. For DMD, distribution is specialist-led through neuromuscular centers and genetic testing, not retail pharmacies. In 2025, Roche extends SRP-9001 ex-U.S., while 5 named research partners help move programs into expert care sites.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace factor\u003c\/th\u003e\n\u003cth\u003e2025\/2026 fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHQ\u003c\/td\u003e\n\u003ctd\u003eCambridge, Massachusetts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel\u003c\/td\u003e\n\u003ctd\u003eSpecialty neuromuscular care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEx-U.S. reach\u003c\/td\u003e\n\u003ctd\u003eRoche partnership\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollabs\u003c\/td\u003e\n\u003ctd\u003e5 named partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eSarepta Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Sarepta Therapeutics 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully detailed on Product, Price, Place, and Promotion with editable charts and actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDMD mutation education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. promotes DMD mutation education by teaching which exon subtypes match each therapy, because treatment is mutation specific. The DMD gene has 79 exons, so genetic confirmation is the gatekeeper for eligibility and dosing. This matters in a rare disease that affects about 1 in 3,500 to 5,000 male births.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeuromuscular specialist engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeuromuscular specialist engagement is highly targeted because Sarepta Therapeutics, Inc. mainly sells to neurologists and neuromuscular centers that diagnose Duchenne muscular dystrophy, the key prescribers for its therapies. This focus matches a 2024 net product revenue base of about $1.7 billion, showing how concentrated specialist access can drive sales. It also means promotion centers on expert conferences, peer education, and center-level outreach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical congress and publication strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. uses medical congresses and peer reviewed publications to share clinical data on Duchenne and other rare diseases, which helps build trust with physicians and payers. In 2024, Sarepta reported about $1.9 billion in net product revenue, and scientific data helps support that commercial reach. This is a standard rare disease play: show outcomes early, then back them with published evidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient advocacy and community outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. uses patient advocacy and community outreach to reach Duchenne muscular dystrophy families, where rare-disease awareness often drives diagnosis and referral. In 2025, Sarepta reported net product revenue of $1.88 billion, showing how closely education and treatment access are linked. These programs also help connect caregivers with testing and specialist care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets Duchenne patient and caregiver groups\u003c\/li\u003e\n\u003cli\u003eBuilds diagnosis and referral pathways\u003c\/li\u003e\n\u003cli\u003eSupports rare-disease awareness networks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCorporate and partnership communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. leans on investor relations and press releases to share regulatory milestones, pipeline updates, and partnership news. That matters in a narrow Duchenne muscular dystrophy market, where each FDA update can move sentiment fast. Its public channels keep the brand visible and its story easy to track.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory wins get immediate coverage.\u003c\/li\u003e\n\u003cli\u003ePipeline news supports investor trust.\u003c\/li\u003e\n\u003cli\u003ePartnership updates widen reach.\u003c\/li\u003e\n\u003cli\u003ePress releases carry most messages.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta’s Specialist-First Play Drives Rare-Disease Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. promotes mutation testing first, because Duchenne muscular dystrophy therapies are exon specific and only fit certain genotypes. It targets neuromuscular specialists, rare-disease centers, and patient groups, since they drive diagnosis and referral. In 2025, net product revenue was $1.88 billion, showing how specialist education supports sales. Medical congresses, peer-reviewed data, and advocacy outreach do most of the work.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePromotion lever\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003cth\u003e2025\/2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenetic education\u003c\/td\u003e\n\u003ctd\u003eMatches therapy to exon subtype\u003c\/td\u003e\n\u003ctd\u003eDMD has 79 exons\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialist outreach\u003c\/td\u003e\n\u003ctd\u003eReaches key prescribers\u003c\/td\u003e\n\u003ctd\u003e2025 net product revenue: $1.88B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvocacy and congresses\u003c\/td\u003e\n\u003ctd\u003eBuilds trust and referrals\u003c\/td\u003e\n\u003ctd\u003eRare disease focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEXONDYS 51 about 300000 annual list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEXONDYS 51 is priced as a high-cost U.S. rare-disease therapy, with a public list price of about $300,000 a year. The recurring spend comes from chronic weekly dosing, so total revenue is driven by long treatment duration, not one-time use. For Sarepta Therapeutics, Inc., that makes price a key lever in the rare-disease market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVYONDYS 53 about 300000 annual list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVYONDYS 53 uses a high-cost orphan-drug price model, with public U.S. list pricing around $300,000 a year. Its weekly IV dosing supports repeat use, which helps Sarepta Therapeutics, Inc. keep revenue recurring across the treatment year. The price also reflects its niche Duchenne muscular dystrophy market and limited patient pool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMONDYS 45 about 300000 annual list price\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAMONDYS 45 carries a public list price near 300000 dollars per year, making it a high-cost Duchenne muscular dystrophy therapy. Sarepta Therapeutics positions it as a mutation-specific, chronic treatment, so pricing reflects long-term use in a narrow patient pool. In 2023, Sarepta reported AMONDYS 45 net product sales of about 161 million dollars, showing the drug’s material role in the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eELEVIDYS 3 2 million one time\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. prices ELEVIDYS as a one-time gene therapy at $3.2 million in the United States, so the revenue model is a single premium payment rather than recurring sales. That is a sharp break from weekly exon-skipping therapy, which depends on repeated dosing and steady long-term use. It also makes payer access and reimbursement the key price hurdle.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne-time list price: $3.2 million\u003c\/li\u003e\n\u003cli\u003eU.S. gene therapy model\u003c\/li\u003e\n\u003cli\u003eDiffers from weekly exon-skipping\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePrior authorization and reimbursement support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCoverage for Sarepta Therapeutics, Inc. depends on confirmed genetic eligibility and payer approval, so price is tied to access more than list value. Specialty drugs in this class usually need prior authorization before payment, and that can slow therapy start. Sarepta offsets this by pairing price with reimbursement support, helping teams submit the right proof and move payer reviews faster.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGenetic testing drives coverage.\u003c\/li\u003e\n\u003cli\u003ePrior authorization is usually required.\u003c\/li\u003e\n\u003cli\u003eAccess support reduces payment friction.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta’s Premium Pricing: $300K\/Year Drugs and a $3.2M Gene Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta Therapeutics, Inc. uses premium orphan-drug pricing: EXONDYS 51, VYONDYS 53, and AMONDYS 45 each carry about $300,000 a year in U.S. list price, while ELEVIDYS is priced at $3.2 million one time.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDrug\u003c\/th\u003e\n\u003cth\u003ePrice\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEXONDYS 51\u003c\/td\u003e\n\u003ctd\u003e~$300k\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eELEVIDYS\u003c\/td\u003e\n\u003ctd\u003e$3.2M one-time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234921849097,"sku":"srpt-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/srpt-marketing-mix.webp?v=1785732473","url":"https:\/\/dcfanalyst.com\/products\/srpt-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}